The development of restorative heart valves and blood vessels is set to be accelerated by this EIB financing.
The European Investment Bank (EIB) has signed a €15 million financing agreement with medical technology company Xeltis, based in Eindhoven in the Netherlands. Xeltis is pioneering a restorative approach in heart valve replacement and vascular therapies, a technology that stems in part from research at Eindhoven University of Technology.